Investors

 

Experience cutting edge cancer treatments with Isoray.

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

 

Investor Resources

Governance

Research Analyst Coverage

Ascendiant Capital Markets
Edward Woo

Dawson James Securities Inc.
Jason Kolbert

H.C. Wainwright & Co.
Swayampakula Ramakanth, Ph.D.

Investor News Alerts

Use the button below to email us and receive the latest investor focused news from Isoray.

Do you have questions?

We’ll put you in touch with someone to answer any of your investor related questions.

Our Management Team

 

Isoray Announces Record First Quarter Fiscal 2020 Financial Results

Record Revenue and Gross Profit Revenue Increased 48% Year-Over-Year  RICHLAND, WASHINGTON – November 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR),...

Isoray To Announce First Quarter Fiscal 2020 Financial Results on November 12, 2019

Conference Call is Tuesday, November 12, 2019 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – October  31, 2019 – Isoray, Inc. (NYSE AMERICAN:...

Isoray Will Have Prominent Role at American Brachytherapy Society’s Annual Prostate Brachytherapy Workshop

RICHLAND, WASHINGTON – October 29, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR)  announced today that it will demonstrate its latest products at the...

Isoray Announces Fourth Quarter and Full-Year Fiscal 2019 Financial Results

Record Full Year Revenue Driven by 27% Growth in the Company’s Core Prostate Brachytherapy RICHLAND, WASHINGTON – September 24, 2019 – Isoray, Inc....

A Decade of Data Shows the Value of Isoray’s Cesium-131 As Prostate Cancer Internal Radiation Therapy Treatment

Overall Ten-Year Biochemical Success Rate for Entire Group Was 96.2% Largest and Longest Followed Series of Cesium-131 Treated Patients Reported to...